Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 6.64B P/E 28.74 EPS this Y 27.80% Ern Qtrly Grth 235.20%
Income 231.06M Forward P/E 18.47 EPS next Y 39.10% 50D Avg Chg -5.00%
Sales 1.43B PEG 0.53 EPS past 5Y 74.48% 200D Avg Chg 5.00%
Dividend N/A Price/Book 2.98 EPS next 5Y 46.00% 52W High Chg -18.00%
Recommedations 1.90 Quick Ratio 5.19 Shares Outstanding 320.18M 52W Low Chg 33.00%
Insider Own 2.14% ROA 7.54% Shares Float 297.41M Beta 0.78
Inst Own 85.11% ROE 11.30% Shares Shorted/Prior 6.85M/9.02M Price 20.69
Gross Margin 96.32% Profit Margin 16.10% Avg. Volume 2,224,940 Target Price 27.17
Oper. Margin 19.98% Earnings Date May 10 Volume 2,737,038 Change 2.12%
Exelixis, Inc. News
10:00 AM Buying These 3 Stocks Could Be the Smartest Investing Move You Ever Make
05/13/22 Exelixis, Inc. (NASDAQ:EXEL) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
05/11/22 Exelixis (EXEL) Q1 Earnings Beat, Revenues Miss Estimates
05/10/22 Exelixis (EXEL) Tops Q1 Earnings Estimates
05/10/22 Exelixis Announces First Quarter 2022 Financial Results and Provides Corporate Update
05/09/22 Why Exelixis (EXEL) Might Surprise This Earnings Season
05/04/22 Exelixis To Webcast Fireside Chats as Part of Investor Conferences in May
05/03/22 Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
05/03/22 Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
05/03/22 Ipsen - Exelixis' Cabometyx Scores European Approval As Second-Line Treatment For Thyroid Cancer
04/29/22 Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
04/26/22 Exelixis to Release First Quarter 2022 Financial Results on Tuesday, May 10, 2022
04/26/22 Here's How Much You'd Have If You Invested $1000 in Exelixis a Decade Ago
04/26/22 Phathom Pharmaceuticals Appoints Frank Karbe to its Board of Directors
04/25/22 IBD Stock Of The Day: Exelixis And The Next Opportunity To Spark Shares
04/20/22 California biotech firm scouting sites in Philadelphia suburbs to develop new 200,000-square-foot campus
04/19/22 Exelixis (EXEL) Outperforms Industry YTD: What Lies Ahead?
04/18/22 Exelixis (EXEL) Initiates Early Stage Study of Lymphoma
04/14/22 Exelixis Announces Initiation of First-In-Human Phase 1 Trial Evaluating XL114 Monotherapy in Patients with Non-Hodgkin’s Lymphoma

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

EXEL Chatroom

User Image EarningsInsider Posted - 15 hours ago

$EXEL updates FY 2022 guidance to EPS and revenue guidance to $1.52 billion-$1.63 billion. https://www.marketbeat.com/g/98711

User Image txmdgod Posted - 1 day ago

$EXEL we need a PR concerning what we're going to be using our 2 Billion in cash for... Let's acquire someone or buyback stock. C'mon bod

User Image tickeron Posted - 2 days ago

Do you agree with the A.I. prediction? $EXEL enters a Downtrend as Momentum Indicator dropped below the 0 level on April 28, 2022. View odds for this and other indicators: https://srnk.us/go/3666575

User Image KY3000 Posted - 2 days ago

$EXEL massive tomorrow if favorable trial proceedings

User Image Insider_Analysis Posted - 2 days ago

$EXEL Lance Willsey sold 40,000 shares [High Conviction] https://insider-analysis.com/search_transactions.php?ticker=TABLE_EXEL

User Image Aigner_Andreas Posted - 3 days ago

#GIndustry #BUY WK18 $JAZZ, $INCY, $EXEL, $REGN, $VRTX, TECH #Biotech #Biotechnology IBB LABD LABU XBI BIB UBIO #growthstocks #stocks #finance #investment

User Image Insider_Analysis Posted - 3 days ago

$EXEL Glassman Wealth Services increased their holdings by 8,689%, one of the largest institutional increases this quarter https://insider-analysis.com/search_whales.php?ticker=TABLE_EXEL

User Image NASA10 Posted - 3 days ago

$EXEL cash cow for the insiders still in play 😂😂😂

User Image MarketBeatInsiderTrades Posted - 3 days ago

Exelixis Director Lance Willsey Sells $786,000.00 in $EXEL https://www.marketbeat.com/i/509267

User Image Insider_Analysis Posted - 3 days ago

$EXEL In the recent reporting quarter: 26 institutions initiated a position, while 14 completely liquidated https://insider-analysis.com/search_whales.php?ticker=TABLE_EXEL

User Image cctranscripts Posted - 3 days ago

Exelixis director just cashed-in 40,000 options https://www.conferencecalltranscripts.com/summary/?id=10848368 $EXEL

User Image Quantisnow Posted - 3 days ago

$EXEL 📜 SEC Form 4: Willsey Lance exercised 40,000 shares at a strike of $3.13 and sold $786,000 worth of shares (40,000 units at $19.65) https://quantisnow.com/i/2888171?utm_source=stocktwits 45 seconds delayed.

User Image fla Posted - 3 days ago

$EXEL [15s. delayed] filed SEC form 4: Director WILLSEY LANCE: Disposed 40,000 of Common Stock at price $19.65 and Converted securities 4 https://s.flashalert.me/iIFH7s

User Image risenhoover Posted - 3 days ago

Insider Lance Willsey reports selling 40,000 shares of $EXEL for a total cost of $786,000.00 https://fintel.io/n/us/exel/willsey-lance?utm_source=stocktwits.com&utm_medium=Referral&utm_campaign=insider

User Image Newsfilter Posted - 3 days ago

$EXEL Form 4 (statement of changes in beneficial ownership of securities) filed with the SEC https://newsfilter.io/a/42a1209dcc1511be9345fe3bd22bf296

User Image EarningsInsider Posted - 4 days ago

Oppenheimer Raises Exelixis FY2024 Earnings Estimates to $1.56 EPS (Previously $1.55). https://www.marketbeat.com/x/1237523 $EXEL

User Image NASA10 Posted - 4 days ago

$EXEL 😂😂😂

User Image MarketBeat Posted - 5 days ago

Exelixis initiated by Jefferies Financial Group Inc. at buy. $28.00 PT. https://www.marketbeat.com/r/1764292 $EXEL

User Image Aigner_Andreas Posted - 5 days ago

#GSector #BUY WK18 $PCRX, $JAZZ, $INCY, $EXEL, $HCA, HZNP, MRK, SYNH, REGN, NUVA #Healthcare IBB LABD LABU XBI BIB UBIO XLV IHF IHI IHE #growthstocks #stocks #finance #investment

User Image Tangle22 Posted - 5 days ago

$EXEL is ok then $BHC ?

User Image StockInvest_us Posted - 5 days ago

Signal alert: $EXEL - Possible Runner https://stockinvest.us/stock/EXEL?utm_source=stocktwits&utm_medium=autopost&utm_campaign=autopost

User Image troy14 Posted - 5 days ago

$EXEL @NASA10 Hey Biodick. Thanks a second time for helping me win $50. Bet the same two dudes I work with that you would have some moronic remarks about Exel after their report. Soooo predictable!!

User Image LHBhandy Posted - 6 days ago

$EXEL we really need SteveTexans back!!!

User Image jgarn Posted - 6 days ago

$EXEL we need our boy @jedi_delta to come back

User Image NASA10 Posted - 6 days ago

$EXEL 🤮

User Image tickeron Posted - 6 days ago

This is amazing! What do you think? $EXEL enters a Downtrend because Momentum Indicator dropped below the 0 level on April 28, 2022. View odds for this and other indicators: https://srnk.us/go/3654183

User Image StockInvest_us Posted - 6 days ago

Signal alert: $EXEL - Possible Runner https://stockinvest.us/stock/EXEL?utm_source=stocktwits&utm_medium=autopost&utm_campaign=autopost

User Image cctranscripts Posted - 6 days ago

Nice explanations put forth in relation to $EXEL call (transcript) http://conferencecalltranscripts.org/?co=EXEL.US

User Image STCKPRO Posted - 6 days ago

$EXEL NEW ARTICLE : Exelixis, Inc. (EXEL) CEO Mike Morrissey on Q1 2022 Results - Earnings Call Transcript https://www.stck.pro/news/EXEL/27522390

User Image EarningsInsider Posted - 6 days ago

Exelixis announces earnings. $0.21 EPS. Beats estimates. $356.00m revenue. https://www.marketbeat.com/s/564948 $EXEL

Analyst Ratings
HC Wainwright & Co. Buy Feb 18, 22
RBC Capital Outperform Nov 3, 21
HC Wainwright & Co. Buy Nov 3, 21
Oppenheimer Outperform Nov 2, 21
Jefferies Buy Oct 7, 21
Truist Securities Buy Sep 20, 21
Needham Buy Jun 28, 21
HC Wainwright & Co. Buy Jun 15, 21
Morgan Stanley Equal-Weight Apr 19, 21
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
WILLSEY LANCE Director Director May 12 Option 3.13 40,000 125,200 464,415 05/13/22
WILLSEY LANCE Director Director May 12 Sell 19.65 40,000 786,000 424,415 05/13/22
WYSZOMIERSKI JACK L Director Director Apr 04 Option 3.13 40,000 125,200 279,888 04/06/22
WYSZOMIERSKI JACK L Director Director Apr 04 Sell 23 6,696 154,008 273,192 04/06/22
Haley Patrick J. EVP, Commercial EVP, Commercial Mar 31 Option 6.21 20,000 124,200 279,191 04/04/22
Haley Patrick J. EVP, Commercial EVP, Commercial Mar 31 Sell 22.72 20,000 454,400 269,191 04/04/22
Hessekiel Jeffrey EVP, General Counsel.. EVP, General Counsel & Sec Mar 28 Sell 22 18,000 396,000 605,236 03/30/22
Garber Alan M Director Director Mar 01 Option 3.13 40,000 125,200 52,718 03/03/22
Garber Alan M Director Director Mar 01 Sell 21 21,301 447,321 31,417 03/03/22
Hessekiel Jeffrey EVP and General Coun.. EVP and General Counsel Feb 24 Sell 20 18,000 360,000 555,361 02/28/22
Haley Patrick J. EVP, Commercial EVP, Commercial Feb 25 Sell 19.53 31,238 610,078 198,476 02/28/22
PAPADOPOULOS STELIOS Director Director Feb 22 Sell 19.56 84,515 1,653,113 1,220,036 02/24/22
FELDBAUM CARL B Director Director Feb 22 Option 3.13 20,000 62,600 28,521 02/24/22
FELDBAUM CARL B Director Director Feb 22 Sell 19.49 20,000 389,800 8,521 02/24/22
Haley Patrick J. EVP, Commercial EVP, Commercial Feb 03 Option 1.9 60,000 114,000 305,241 02/04/22
Haley Patrick J. EVP, Commercial EVP, Commercial Feb 03 Sell 17.91 60,000 1,074,600 245,241 02/04/22
Lamb Peter EVP, Scientific Stra.. EVP, Scientific Strategy & CSO Dec 15 Option 6.21 47,500 294,975 410,672 12/17/21
Lamb Peter EVP, Scientific Stra.. EVP, Scientific Strategy & CSO Dec 15 Sell 17.44 47,500 828,400 363,172 12/17/21
Lamb Peter EVP, Scientific Stra.. EVP, Scientific Strategy & CSO Oct 15 Option 6.21 47,500 294,975 458,740 10/15/21
Lamb Peter EVP, Scientific Stra.. EVP, Scientific Strategy & CSO Oct 15 Sell 21.92 47,500 1,041,200 411,240 10/15/21
Haley Patrick J. EVP, Commercial EVP, Commercial Sep 17 Sell 20.36 25,000 509,000 280,994 09/17/21
Haley Patrick J. EVP, Commercial EVP, Commercial Sep 17 Option 1.7 25,000 42,500 305,994 09/17/21
Lamb Peter EVP, Scientific Stra.. EVP, Scientific Strategy & CSO Sep 17 Sell 20.46 47,500 971,850 389,467 09/17/21
Lamb Peter EVP, Scientific Stra.. EVP, Scientific Strategy & CSO Sep 17 Option 6.21 47,500 294,975 436,967 09/17/21
Lamb Peter EVP, Scientific Stra.. EVP, Scientific Strategy & CSO Aug 18 Option 1.9 55,000 104,500 444,467 08/18/21
Lamb Peter EVP, Scientific Stra.. EVP, Scientific Strategy & CSO Aug 18 Sell 18.44 55,000 1,014,200 389,467 08/18/21
COHEN CHARLES Director Director Jul 08 Option 4.72 80,000 377,600 261,375 07/08/21
Haley Patrick J. EVP, Commercial EVP, Commercial May 18 Sell 24.73 14,593 360,885 280,994 05/18/21
MARCHESI VINCENT T Director Director May 17 Option 6.3 40,000 252,000 106,115 05/17/21
MORRISSEY MICHAEL President and CEO President and CEO May 14 Option 4.2 50,000 210,000 541,813 05/14/21
Schwab Gisela Pres, Prod Dev & Med.. Pres, Prod Dev & Med Aff & CMO May 14 Option 1.9 100,000 190,000 714,078 05/14/21
Schwab Gisela Pres, Prod Dev & Med.. Pres, Prod Dev & Med Aff & CMO May 14 Sell 25.38 100,000 2,538,000 614,078 05/14/21
Schwab Gisela Pres, Prod Dev & Med.. Pres, Prod Dev & Med Aff & CMO Apr 28 Option 1.7 50,000 85,000 663,482 04/28/21
Lamb Peter EVP, Scientific Stra.. EVP, Scientific Strategy & CSO Apr 02 Option 1.7 60,000 102,000 449,467 04/02/21
Schwab Gisela Pres, Prod Dev & Med.. Pres, Prod Dev & Med Aff & CMO Apr 02 Option 1.7 50,000 85,000 663,482 04/02/21
Schwab Gisela Pres, Prod Dev & Med.. Pres, Prod Dev & Med Aff & CMO Apr 02 Sell 23 50,000 1,150,000 613,482 04/02/21
Lamb Peter EVP, Scientific Stra.. EVP, Scientific Strategy & CSO Mar 03 Sell 22.11 65,000 1,437,150 340,072 03/03/21
Lamb Peter EVP, Scientific Stra.. EVP, Scientific Strategy & CSO Mar 03 Option 1.7 65,000 110,500 405,072 03/03/21
COHEN CHARLES Director Director Feb 26 Option 3.38 40,000 135,200 221,375 02/26/21
COHEN CHARLES Director Director Feb 26 Sell 22.69 40,000 907,600 181,375 02/26/21
WILLSEY LANCE Director Director Feb 24 Option 3.38 40,000 135,200 464,415 02/24/21
WILLSEY LANCE Director Director Feb 24 Sell 22.05 90,000 1,984,500 424,415 02/24/21
Schwab Gisela Pres, Prod Dev & Med.. Pres, Prod Dev & Med Aff & CMO Feb 19 Option 1.7 100,000 170,000 590,597 02/19/21
Schwab Gisela Pres, Prod Dev & Med.. Pres, Prod Dev & Med Aff & CMO Feb 19 Sell 22.43 100,000 2,243,000 540,597 02/19/21
Haley Patrick J. EVP, Commercial EVP, Commercial Feb 17 Sell 21.57 45,000 970,650 246,887 02/17/21
FELDBAUM CARL B Director Director Feb 17 Option 3.38 20,000 67,600 28,521 02/17/21
FELDBAUM CARL B Director Director Feb 17 Sell 21.96 20,000 439,200 8,521 02/17/21
Lamb Peter EVP, Scientific Stra.. EVP, Scientific Strategy & CSO Feb 03 Option 1.7 65,000 110,500 348,124 02/03/21
Lamb Peter EVP, Scientific Stra.. EVP, Scientific Strategy & CSO Feb 03 Sell 22.08 65,000 1,435,200 283,124 02/03/21
Senner Christopher J. EVP and CFO EVP and CFO Jan 14 Option 3.66 30,000 109,800 275,596 01/14/21